Binding of Neu Differentiation Factor with the Extracellular Domain of Her2 and Her3 (*)

  title={Binding of Neu Differentiation Factor with the Extracellular Domain of Her2 and Her3 (*)},
  author={Thomas P. Horan and Jie Wen and Tsutomu Arakawa and N G Liu and David W. Brankow and S Hu and Barry Joseph Ratzkin and John S. Philo},
  journal={The Journal of Biological Chemistry},
  pages={24604 - 24608}
The interaction of neu differentiation factor (NDF) with the extracellular domains of Her2 (sHer2) and Her3 (sHer3) have been studied using native gels, light scattering, and sedimentation equilibrium. The full-length NDFβ2 was shown to bind sHer3 with a dissociation constant of 26 ± 9 nM, while it showed a 1000-fold weaker binding to sHer2. Taken together, these results demonstrate that NDF is a high affinity ligand for Her3, but not for Her2. No increase in affinity of the NDFβ2 for sHer3 was… 

Figures from this paper

Identification of a Heregulin Binding Site in HER3 Extracellular Domain*
The biochemical findings reinforce the structural hypothesis of others that HER3-ECDI–IV is similar to the insulin-like growth factor-1 receptor (IGF-1R), as follows: the protected cleavage site in HER3–IVresponds to a binding footprint in domain I of IGF-1 R, supporting the hypothesis that domain I is involved in ligand binding.
Identification of a Region within the ErbB2/HER2 Intracellular Domain That Is Necessary for Ligand-independent Association*
A short amino acid segment comprising amino acids 966–968 in the intracellular domain that seemingly disrupts receptor-receptor association that is driven either by overexpression or mutation in the transmembrane region is defined.
ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
Structural studies of the tightly ligand‐regulated Drosophila melanogaster EGFR (dEGFR) are presented that challenge the notion that ErbB2 lacks autoinhibition, and argue that normal and pathogenic Erb B2 signaling may also be ligand-regulated.
Regulation of Cyclooxygenase-2 pathway by HER2 receptor
These findings provide the first biochemical evidence of a possible role of the COX-2 pathway in the mitogenic action of NDF in colorectal cancer cells where it may be constitutively upregulated due to the autocrine/paracrine activation of HER2/HER3 heterodimers.
Structural and functional investigation of the C-terminal intrinsically disordered fragment of ErbB2
It is shown that despite its lack of any stable structure, this proline-rich region exhibits several transient secondary structures and a long-range contact that might participate in the regulation of its intra- and inter-molecular interactions.
The N-terminal Domains of Neuregulin 1 Confer Signal Attenuation*
The data suggest that whereas the EGF-likedomain of neuregulin 1 is required and sufficient for the formation of active receptor heterodimers, the presence of the N-terminal Ig-like domain is required for efficient signal attenuation.
Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family
Results from long-timescale molecular dynamics simulations indicating that a single ligand is necessary and sufficient to stabilize the ectodomain interface of Her2 heterodimers, which assume an asymmetric conformation similar to that of dEGFR dimers suggest a dimerization mechanism that has been conserved in the evolution of the EGFR family from Drosophila to human.
The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes*
A role for TM domain interactions in ErbB receptor function is suggested, possibly in stabilizing inactive ligand-independent receptor dimers that have been observed by several groups.


Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.
The findings suggest that this ligand-receptor interaction may play a role in the growth and differentiation of some normal and transformed cells.
Cell‐type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER‐2 suggests complex ligand‐receptor relationships.
It is shown that NDF affects tyrosine phosphorylation of Neu in human tumor cells of breast, colon and neuronal origin, but not in ovarian cells that overexpress the receptor.
Heregulin induces tyrosine phosphorylation of HER4/p180erbB4
Findings suggest that activation of the HER4 receptor is involved in signal transduction by heregulin, a specific ligand for HER4 that fails to induce phosphorylation of HER2 in the absence of HER4.
NDF/heregulin stimulates the phosphorylation of Her3/erbB3
The erbB3 gene product is a receptor for heregulin.
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
The heregulin/neu differentiation factor gene products were purified and cloned based on their ability to stimulate the phosphorylation of a 185-kDa protein in human breast carcinoma cell lines known to express erbB2, indicating that other components besides erBB2 may be required forHeregulin binding.
Studies on the Structure and Function of Glycosylated and Nonglycosylated neu Differentiation Factors
Western blot analysis and quantitative binding assays identify that an NDF preparation produced naturally from Rat1-EJ cells contains both α and β isoforms in a 3 to 2 ratio, and NDF-α and -β isoforms share similar gross protein conformations but are biologically distinct.
The extracellular domain of the epidermal growth factor receptor. Studies on the affinity and stoichiometry of binding, receptor dimerization and a binding-domain mutant.
It is shown, using sedimentation equilibrium analysis, that ligand binding induces significant dimerization of the EGFR extracellular domain, and identified amino acid residues which are close to the binding site since they are common to the epitopes of several ligand-competitive monoclonal antibodies.
Identification of Heregulin, a Specific Activator of p185erbB2
Several complementary DNA clones encoding related HRGs were identified, all of which are similar to proteins in the epidermal growth factor family, and heregulin transcripts were identified in several normal tissues and cancer cell lines.